Successful alemtuzumab retreatment in multiple sclerosis following previous diffuse alveolar haemorrhage.

Alemtuzumab-induced diffuse alveolar haemorrhage (DAH) is a rare but serious complication in people with relapsing-remitting multiple sclerosis (RRMS). Evidence supporting retreatment despite adverse events remains limited. We report a 29-year-old female who developed DAH during the first alemtuzumab cycle and was subsequently retreated 1 year later following interdisciplinary advice from respiratory.